Sandbox: Reddy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(973 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Candida Vulvovaginitis}}
{{CMG}}; {{AE}}{{AKI}}
{{SK}} Vulvovaginal candidiasis, Candidal Vulvovaginitis, Fungal Vaginitis, Yeast infection, Vulvovaginal Candidosis
==Overview==
Candida vulvovagintis is an infection of the vagina and the vestibulum, common in women in the reproductive age group. It is caused by various Candida species with Candida albicans most common pathogen followed by other species like C.glabarta, C.krusei etc. Patients present with vulvar pruritus, burning micturition and vaginal discharge.The diagnosis of candidal infection requires a collaboration of clinical and diagnostic findings. Patients have typical white cottage chesee like discharge with hyphae and spores demonstrated on microscopy. Patients with uncomplicated infection respond well to topical and oral azole therapy. 5 to 8% of women develop recurrent vaginitis, which is defined as more than 4 episodes in a year. These patients require a longer duration of therapy with an induction and maintenance phase.
==Historical Perspective==
*In 1839, B. Lagenbeck from Germany described a yeast-like fungus for the first time in the human oral infection "thrush." and its ability to cause it.<ref name="pmid18509848">{{cite journal |vauthors=Barnett JA |title=A history of research on yeasts 12: medical yeasts part 1, Candida albicans |journal=Yeast |volume=25 |issue=6 |pages=385–417 |year=2008 |pmid=18509848 |doi=10.1002/yea.1595 |url=}}</ref>
*In 1923 the Candida albicans was described by Christine Marie Berkhout.  Over the years the classification of the genera and species has evolved. Obsolete names for this genus include ''Mycotorula'' and ''Torulopsis''. The species has also been known in the past as ''Monilia albicans'' and ''Oidium albicans''. The current classification is ''nomen conservandum'', which means the name is authorized for use by the [http://www.bgbm.org/iapt/nomenclature/code/SaintLouis/0000St.Luistitle.htm International Botanical Congress (IBC)].
*The full current taxonomic classification is available at ''[[Candida albicans]]''.
*The genus ''Candida'' includes about 150 different species. However, only a few of those are known to cause human infections. ''C. albicans'' is the most significant pathogenic (=disease-causing) species. Other ''Candida'' species causing diseases in humans include ''C. tropicalis'', ''C. glabrata'', ''C. krusei'', ''C. parapsilosis'', ''C. dubliniensis'', and ''C. lusitaniae''.
==Classification==
[[Candida]] [[vulvovaginitis]] can be classified based on the duration, as well as the strain of [[Candida]] causing the infection. 
===Duration===
[[Candida]] [[vulvovaginitis]] can be divided based on the duration and number of episodes of the infection into:<ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref><ref name="pmid9500475">{{cite journal |vauthors=Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR |title=Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations |journal=Am. J. Obstet. Gynecol. |volume=178 |issue=2 |pages=203–11 |year=1998 |pmid=9500475 |doi= |url=}}</ref><ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid7995997">{{cite journal |vauthors=Vazquez JA, Sobel JD, Demitriou R, Vaishampayan J, Lynch M, Zervos MJ |title=Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis |journal=J. Infect. Dis. |volume=170 |issue=6 |pages=1566–9 |year=1994 |pmid=7995997 |doi= |url=}}</ref>
*'''Acute, uncomplicated''': these are usually sporadic cases of [[Candida]] [[vulvovaginitis]], which respond to topical anti-fungal therapy and have a high cure rate.
*'''Acute, complicated''': symptoms are more severe than uncomplicated infections and typically require a combination of oral and topical anti-fungal treatment.
*'''Recurrent''': defined as 4 or more episodes of [[Candida]] [[vulvovaginitis]] per year, usually caused by the same strain of [[Candida]]. Treatment also requires a combination of oral and topical anti-fungal agents.
===Microbiology===
[[Candida]] [[vulvovaginitis]] can also be divided based on the strain of [[Candida]] causing the infection:<ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid15709796">{{cite journal |vauthors=Buscemi L, Arechavala A, Negroni R |title=[Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital] |journal=Rev Iberoam Micol |volume=21 |issue=4 |pages=177–81 |year=2004 |pmid=15709796 |doi= |url=}}</ref>
*''[[C. albicans]]'': comprises the majority of cases of [[Candida]] [[vulvovaginitis]]
*''C. glabrata'': it is the second most common causative pathogen
*''C. tropicalis''
*''C. krusei''
*''C. parapsilosis''
==Pathophysiology==
===Vaginal Defensive mechanisms aganist Candida===
====Innate Mechanisms====
{| class="wikitable"
!
!Defense
!Mechanism of protection
!Evidence of protection
|-
|1
|Vaginal epithelial cells
|
*In Vitro inhibition of Candida growth<ref name="pmid16239581">{{cite journal| author=Barousse MM, Espinosa T, Dunlap K, Fidel PL| title=Vaginal epithelial cell anti-Candida albicans activity is associated with protection against symptomatic vaginal candidiasis. | journal=Infect Immun | year= 2005 | volume= 73 | issue= 11 | pages= 7765-7 | pmid=16239581 | doi=10.1128/IAI.73.11.7765-7767.2005 | pmc=1273905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16239581  }}</ref>
|
*Protective role in vivo unknown
*Patients with recurrent candida infections have a decreased anti Candida activity
|-
|2
|Mannose-binding lectin
|
*Epithelial-cell associated protein which binds to candida surface mannan.<ref name="pmid18715406" />
*Inhibits Candida growth by activating complement<ref name="pmid15243942">{{cite journal| author=Ip WK, Lau YL| title=Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. | journal=J Infect Dis | year= 2004 | volume= 190 | issue= 3 | pages= 632-40 | pmid=15243942 | doi=10.1086/422397 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15243942  }}</ref>
*Activity is genetically determined
|
*Decreased expression can increase the susceptibility for vaginal colonization of candida and leading to vaginitis.
|-
|3
|Activated lactoferrin<ref name="pmid15603095">{{cite journal| author=Naidu AS, Chen J, Martinez C, Tulpinski J, Pal BK, Fowler RS| title=Activated lactoferrin's ability to inhibit Candida growth and block yeast adhesion to the vaginal epithelial monolayer. | journal=J Reprod Med | year= 2004 | volume= 49 | issue= 11 | pages= 859-66 | pmid=15603095 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15603095  }}</ref>
|
*Fungistatic and fungicidal activity
|
*Role in protection aganist infection is not clear
|-
|4
|Vaginal bacterial flora
|
*Lactobacillus species compete for nutrients.
*Bacteriocins and hydrogen peroxide inhibits yeast growth/germination
|
*Role in protection aganist vaginitis still unclear
|-
|5
|Phagocytic systems/polymononuclear leucocytes, mononuclear cells, complement
|
*Mainly found in lamina propria in experimental vaginitis, help in reducing the yeast load and its invasion by phagocytosis and intracellular killing<ref name="pmid340470">{{cite journal| author=Diamond RD, Krzesicki R, Jao W| title=Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. | journal=J Clin Invest | year= 1978 | volume= 61 | issue= 2 | pages= 349-59 | pmid=340470 | doi=10.1172/JCI108945 | pmc=372545 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=340470  }}</ref>
*Nitric oxide has anti-candida activity
|
*Role in protection still unclear
|}
====Adaptive Mechanisms====
{| class="wikitable"
!
!Defense
!Mechanism
!Role in Protection
|-
|1
|Immunoglobulin mediated immunity
|Systemic IgM, IgG and local IgA antibodies are produced in response to the  infection<ref name="pmid4556009">{{cite journal| author=Waldman RH, Cruz JM, Rowe DS| title=Immunoglobulin levels and antibody to Candida albicans in human cervicovaginal secretions. | journal=Clin Exp Immunol | year= 1972 | volume= 10 | issue= 3 | pages= 427-34 | pmid=4556009 | doi= | pmc=1713147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4556009  }}</ref>
|
*Protective role not proven.
*Elevated titres of vaginal anti-candida IgG, IgA are detected in women with recurrent vaginitis
*Persistent symptoms could be attributed to Anti-candida IgE<ref name="pmid8809464">{{cite journal| author=Fidel PL, Sobel JD| title=Immunopathogenesis of recurrent vulvovaginal candidiasis. | journal=Clin Microbiol Rev | year= 1996 | volume= 9 | issue= 3 | pages= 335-48 | pmid=8809464 | doi= | pmc=172897 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8809464  }}</ref>
|-
|2
|Cell Mediated Immunity
|
Interleukin 4 (Th2) inhibits anti-candida activity of nitric oxide and protective pro-inflammatory Th1 cytokines.<ref name="pmid15735412">{{cite journal| author=Fidel PL| title=Immunity in vaginal candidiasis. | journal=Curr Opin Infect Dis | year= 2005 | volume= 18 | issue= 2 | pages= 107-11 | pmid=15735412 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735412  }}</ref>
|
*Role in protection from vulvovaginitis is still not clear
*It is still a hypothesis<ref name="pmid15102806">{{cite journal| author=Fidel PL, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH et al.| title=An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. | journal=Infect Immun | year= 2004 | volume= 72 | issue= 5 | pages= 2939-46 | pmid=15102806 | doi= | pmc=387876 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15102806  }}</ref>
*Patients with recurrent infection have undetectable Th2 cytokines.
|}
===Candida Virulence Factors===
*C.albicans in forms vitro blastospores, germ tubes, pseudomycelia, rue mycelia and also chlamydospores on special culture media. C. glabrata exists exclusively in blastospores.
*All strains of Candida species possess a yeast surface mannoprotein which helps in adhering to epithelial cells of the vagina.<ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid3895958">{{cite journal |vauthors=Sobel JD |title=Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis |journal=Am. J. Obstet. Gynecol. |volume=152 |issue=7 Pt 2 |pages=924–35 |year=1985 |pmid=3895958 |doi= |url=}}</ref>
*Germination of the spores helps in colonizing the vagina.<ref name="pmid6327527">{{cite journal| author=Sobel JD, Muller G, Buckley HR| title=Critical role of germ tube formation in the pathogenesis of candidal vaginitis. | journal=Infect Immun | year= 1984 | volume= 44 | issue= 3 | pages= 576-80 | pmid=6327527 | doi= | pmc=263631 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6327527  }} </ref>
*Proteolytic enzymes, toxins and phospholipase destroy the proteins that normally impair fungal invasion, enhancing the ability of [[Candida]] to colonize the vagina.<ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid3895958">{{cite journal |vauthors=Sobel JD |title=Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis |journal=Am. J. Obstet. Gynecol. |volume=152 |issue=7 Pt 2 |pages=924–35 |year=1985 |pmid=3895958 |doi= |url=}}</ref><ref name="pmid2688924">{{cite journal |vauthors=Sobel JD |title=Pathogenesis of Candida vulvovaginitis |journal=Curr Top Med Mycol |volume=3 |issue= |pages=86–108 |year=1989 |pmid=2688924 |doi= |url=}}</ref><ref name="pmid12761103">{{cite journal| author=Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M et al.| title=The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. | journal=Infect Immun | year= 2003 | volume= 71 | issue= 6 | pages= 3227-34 | pmid=12761103 | doi= | pmc=155757 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12761103  }}</ref>
*Phenotypic switching of Candida is described in patients with recurrent vaginitis.<ref name="pmid3284370">{{cite journal| author=Soll DR| title=High-frequency switching in Candida albicans and its relations to vaginal candidiasis. | journal=Am J Obstet Gynecol | year= 1988 | volume= 158 | issue= 4 | pages= 997-1001 | pmid=3284370 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3284370  }}</ref>
*C.albicans can form bio-films on the intra uterine devices or sponges causing disease recurrence.
===Pathogenesis===
*Candida vulvovaginitis is a microbial disease and not all patients with detectable pathogen are symptomatic. Multiple risk factors and the imbalance in the protective vaginal defenses predispose patients to develop active disease.
*Candida vaginal infections are more common in the reproductive age group because of the high concentration of estrogen. It increases the amount of glycogen in the vagina providing a carbon source for candida organisms to colonize and also increases the adherence of candida to the vaginal epithelial cells.<ref name="pmid11592551">{{cite journal| author=Dennerstein GJ, Ellis DH| title=Oestrogen, glycogen and vaginal candidiasis. | journal=Aust N Z J Obstet Gynaecol | year= 2001 | volume= 41 | issue= 3 | pages= 326-8 | pmid=11592551 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11592551  }}</ref>
*The most common source of the infection is from the peri-anal area. Other less common source is sexual transmission and persistance of organisms in the vagina after treatment, responsible for recurrence.<ref name="pmid333134">{{cite journal| author=Miles MR, Olsen L, Rogers A| title=Recurrent vaginal candidiasis. Importance of an intestinal reservoir. | journal=JAMA | year= 1977 | volume= 238 | issue= 17 | pages= 1836-7 | pmid=333134 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=333134  }}</ref>
*The course of the infection begins with colonization, symptoms appear with the invasion of the blastospores or pseudohyphae of the vaginal wall.<ref name="pmid9880475">{{cite journal| author=Fidel PL, Vazquez JA, Sobel JD| title=Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. | journal=Clin Microbiol Rev | year= 1999 | volume= 12 | issue= 1 | pages= 80-96 | pmid=9880475 | doi= | pmc=88907 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9880475  }}</ref>
*The understanding of the transition from asymptomatic vaginal colonization with [[Candida]] to symptomatic [[vulvovaginitis]] is not clear.<ref name="pmid3895958">{{cite journal |vauthors=Sobel JD |title=Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis |journal=Am. J. Obstet. Gynecol. |volume=152 |issue=7 Pt 2 |pages=924–35 |year=1985 |pmid=3895958 |doi= |url=}}</ref><ref name="pmid2688924">{{cite journal |vauthors=Sobel JD |title=Pathogenesis of Candida vulvovaginitis |journal=Curr Top Med Mycol |volume=3 |issue= |pages=86–108 |year=1989 |pmid=2688924 |doi= |url=}}</ref>
===Genetics===
*Few genetic factors are thought to be involved in patients with recurrent [[Candida]] [[vulvovaginitis]].<ref name="pmid12964847">{{cite journal| author=Calderon L, Williams R, Martinez M, Clemons KV, Stevens DA| title=Genetic susceptibility to vaginal candidiasis. | journal=Med Mycol | year= 2003 | volume= 41 | issue= 2 | pages= 143-7 | pmid=12964847 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12964847  }}</ref>
*Supporting evidence is that many cases were found to be more common in African-American women, run in families, as well as being associated with ABO-Lewis non-secretor phenotype, a rare blood group.
*In addition, women with [[Candida]] [[vulvovaginitis]] were found to have decreased concentrations of [[mannose binding lectin]] (MBL), hence, the variant (MBL) gene is thought to be a contributing factor in the development of [[Candida]] [[vulvovaginitis]].<ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref><ref name="pmid16256117">{{cite journal |vauthors=Liu F, Liao Q, Liu Z |title=Mannose-binding lectin and vulvovaginal candidiasis |journal=Int J Gynaecol Obstet |volume=92 |issue=1 |pages=43–7 |year=2006 |pmid=16256117 |doi=10.1016/j.ijgo.2005.08.024 |url=}}</ref><ref name="pmid18715406">{{cite journal |vauthors=Donders GG, Babula O, Bellen G, Linhares IM, Witkin SS |title=Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis |journal=BJOG |volume=115 |issue=10 |pages=1225–31 |year=2008 |pmid=18715406 |doi=10.1111/j.1471-0528.2008.01830.x |url=}}</ref>


===Gross Pathology===
{{Roseola}}
On speculum examination typical curdy white discharge is present.
{{CMG}}:{{AE}}{{DAMI}}
<gallery>
[http://www.peir.net Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
Image:speculum_vagina.jpg|left|thumb|350px|This photograph is a speculum examination of the vagina with Candida infection and the typical thick, curdy vaginal discharge.
</gallery>
===Microscopic Pathology===
<gallery>
Image:Calbicans.jpg|left|thumb|350px|This is a a microscopic image of Candida albicans, grown on cornmeal agar medium.
<br clear="left"/>


Image:Renal candidiasis 003.jpeg|left|thumb|350px|This is a low-power photomicrograph of lymph node with three prominent areas of Candida colonies (arrows). Even at this low magnification, the purple-staining yeast and pseudohyphae can be easily seen. This section was stained with Periodic Acid-Schiff Hematoxylin (PASH), which stains the cell wall of fungi to make them more easily visible.
<br clear="left"/>


Image:Renal candidiasis 004.jpeg|left|thumb|350px|This is a low-power photomicrograph of one of the Candida colonies from this lymph node. The chains of yeast which are termed "pseudohyphae" are apparent at this magnification.
==[[Roseola overview|Overview]]==
<br clear="left"/>


Image:Renal candidiasis 005.jpeg|left|thumb|350px|This higher-power photomicrograph shows the yeasts and pseudohyphae in this focus of Candida organisms.
==[[Roseola historical perspective|Historical Perspective]]==
<br clear="left"/>


Image:Renal candidiasis 006.jpeg|left|thumb|350px|This high-power photomicrograph shows the yeasts (1) and pseudohyphae (2).
==[[Roseola classification|Classification]]==
<br clear="left"/>


</gallery>
==[[Roseola pathophysiology|Pathophysiology]]==


===Associated Conditions===
==[[Roseola causes|Causes]]==
*[[Candida]] [[vulvovaginitis]] may be associated with other pathogens that cause [[vulvovaginitis]] which include ''Trichomonas vaginalis'' and ''Gardnerella vaginalis''. The presence of these diseases in combination is common therefore they must be excluded before initiation of treatment.<ref name="pmid23354954">{{cite journal |vauthors=Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax SE |title=Mixed vaginitis-more than coinfection and with therapeutic implications |journal=Curr Infect Dis Rep |volume=15 |issue=2 |pages=104–8 |year=2013 |pmid=23354954 |doi=10.1007/s11908-013-0325-5 |url=}}</ref><ref name="pmid15026404">{{cite journal |vauthors=Anderson MR, Klink K, Cohrssen A |title=Evaluation of vaginal complaints |journal=JAMA |volume=291 |issue=11 |pages=1368–79 |year=2004 |pmid=15026404 |doi=10.1001/jama.291.11.1368 |url=}}</ref>


==Causes==
==[[Roseola differential diagnosis|Differentiating Any Disease from other Diseases]]==
Candida vulvovaginitis is caused by many different species of Candida. They are divided into Candida albicans and Candida non-albicans species based on the causative pathogen:
===Common Causes===
*Candida albicans: These strains are isolated in 85 to 95% patients with yeast infection.<ref name="pmid12932875">{{cite journal| author=Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A et al.| title=An epidemiological survey of vulvovaginal candidiasis in Italy. | journal=Eur J Obstet Gynecol Reprod Biol | year= 2003 | volume= 110 | issue= 1 | pages= 66-72 | pmid=12932875 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12932875  }} </ref>
*Candida non albicans: Candida glabrata is the most common isolated pathogen in this group affecting 10 to 20% of women and is associated with recurrent Candida vulvovaginitis.<ref name="pmid15456373">{{cite journal| author=Okungbowa FI, Isikhuemhen OS, Dede AP| title=The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. | journal=Rev Iberoam Micol | year= 2003 | volume= 20 | issue= 2 | pages= 60-3 | pmid=15456373 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15456373  }} </ref>
===Less Common Causes===
These are less commonly isolated in patients but is important to identify the species as they are less sensitive to standard azole therapy causing recurrent infection.<ref name="pmid12237629">{{cite journal| author=Bauters TG, Dhont MA, Temmerman MI, Nelis HJ| title=Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. | journal=Am J Obstet Gynecol | year= 2002 | volume= 187 | issue= 3 | pages= 569-74 | pmid=12237629 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12237629  }} </ref><ref name="pmid12794215">{{cite journal| author=Holland J, Young ML, Lee O, C-A Chen S| title=Vulvovaginal carriage of yeasts other than Candida albicans. | journal=Sex Transm Infect | year= 2003 | volume= 79 | issue= 3 | pages= 249-50 | pmid=12794215 | doi= | pmc=1744683 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12794215  }} </ref>
*Candida parapsilosis<ref name="pmid16040326">{{cite journal| author=Nyirjesy P, Alexander AB, Weitz MV| title=Vaginal Candida parapsilosis: pathogen or bystander? | journal=Infect Dis Obstet Gynecol | year= 2005 | volume= 13 | issue= 1 | pages= 37-41 | pmid=16040326 | doi=10.1080/10647440400025603 | pmc=1784559 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16040326  }} </ref>
*Candida tropicalis
*Candida krusei<ref name="pmid12384840">{{cite journal| author=Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA| title=Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. | journal=Clin Infect Dis | year= 2002 | volume= 35 | issue= 9 | pages= 1066-70 | pmid=12384840 | doi=10.1086/343826 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12384840  }} </ref>


==Differentiating Candida Vulvovaginitis from other Diseases==
==[[Roseola epidemiology and demographics|Epidemiology and Demographics]]==
Candida Vulvovaginitis must be differentiated from the following diseases which have a similar presentation:<ref name=CDC-BV> Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines. Bacterial Vaginosis. http://www.cdc.gov/std/tg2015/bv.htm Accessed on October 13, 2016 </ref><ref name="pmid10839558">{{cite journal| author=Bachmann GA, Nevadunsky NS| title=Diagnosis and treatment of atrophic vaginitis. | journal=Am Fam Physician | year= 2000 | volume= 61 | issue= 10 | pages= 3090-6 | pmid=10839558 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10839558  }} </ref><ref name="pmid2448502">{{cite journal| author=Krieger JN, Tam MR, Stevens CE, Nielsen IO, Hale J, Kiviat NB et al.| title=Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. | journal=JAMA | year= 1988 | volume= 259 | issue= 8 | pages= 1223-7 | pmid=2448502 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2448502  }} </ref><ref name="pmid21422855">{{cite journal| author=Sobel JD, Reichman O, Misra D, Yoo W| title=Prognosis and treatment of desquamative inflammatory vaginitis. | journal=Obstet Gynecol | year= 2011 | volume= 117 | issue= 4 | pages= 850-5 | pmid=21422855 | doi=10.1097/AOG.0b013e3182117c9e | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21422855  }} </ref><ref name="pmid97946645">{{cite journal| author=Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK| title=Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. | journal=Obstet Gynecol | year= 1998 | volume= 92 | issue= 5 | pages= 757-65 | pmid=9794664 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9794664  }}</ref>


{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
==[[Roseola risk factors|Risk Factors]]==  
|+
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Findings}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Trichomoniasis]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Presents with purulent, malodorous, thin discharge associated with burning, [[pruritus]], and [[dysuria]], with the sign of vaginal [[inflammation]] and elevated vaginal [[pH]] (>4.5)
*Motile trichomonads on wet mount
*Positive culture (Gold standard)
*Positive nucleic acid amplification test (NAAT)
|-
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Atrophic vaginitis]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Progressive symptoms 
*Presents with yellow and malodorous vaginal discharge, vaginal dryness, postcoital bleeding, and [[dyspareunia]] with the sign of vaginal [[inflammation]] and elevated vaginal pH (>5)
*Diagnosis is critical and laboratory tests can confirm hypoestrogenic state
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Desquamative inflammatory vaginitis'''
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Chronic clinical syndrome with unknown etiology
*Presents with [[dyspareunia]], dyspareunia, yellow, grey, or green profuse vaginal discharge with the sign of vaginal [[inflammation]] and elevated vaginal pH (>4.5)
*Microscopy shows large number of parabasal (immature squamous epithelial cells) and inflammatory cells
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Bacterial Vaginosis]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*Presents with [[dysuria]]
*Fishy odor (negative whiff test)
*Normal vaginal PH (<4.5)
*On speculum examination signs of vaginal inflammation are demonstrated.
|}


==Epidemiology and Demographics==
==[[Roseola screening|Screening]]==  
*Epidemiological studies on [[Candida]] [[vulvovaginitis]] are hard to perform, because of several factors:<ref name="pmid9500475">{{cite journal |vauthors=Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR |title=Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations |journal=Am. J. Obstet. Gynecol. |volume=178 |issue=2 |pages=203–11 |year=1998 |pmid=9500475 |doi= |url=}}</ref><ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref>
**[[Candida]] [[vulvovaginitis]] is not a reportable disease.
**The diagnosis of [[Candida]] [[vulvovaginitis]] is based on clinical presentation and positive laboratory findings. Relying on a positive culture alone would likely overestimate the prevalence of [[Candida]] [[vulvovaginitis]].
**The use of over-the-counter (OTC) topical anti-fungals makes it difficult to conduct epidemiological studies.
*Candida is the second most common cause of vaginal infection in young women following Bacterial Vaginosis.<ref name="pmid17197596">{{cite journal| author=Allsworth JE, Peipert JF| title=Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. | journal=Obstet Gynecol | year= 2007 | volume= 109 | issue= 1 | pages= 114-20 | pmid=17197596 | doi=10.1097/01.AOG.0000247627.84791.91 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17197596  }} </ref>


=== Age ===
==[[Roseola natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
*Incidence of Candida vulvovaginitis is higher in pregnant women.<ref name="pmid523355">{{cite journal| author=Hurley R, De Louvois J| title=Candida vaginitis. | journal=Postgrad Med J | year= 1979 | volume= 55 | issue= 647 | pages= 645-7 | pmid=523355 | doi= | pmc=2425644 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=523355  }} </ref><ref name="pmid16784126">{{cite journal| author=García Heredia M, García SD, Copolillo EF, Cora Eliseth M, Barata AD, Vay CA et al.| title=[Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents]. | journal=Rev Argent Microbiol | year= 2006 | volume= 38 | issue= 1 | pages= 9-12 | pmid=16784126 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16784126  }} </ref>
*Women in reproductive age group are prone for Candida vulvovaginits and at least one episode is reported in 70 to 75% in this population group.<ref name="ZuckermanRomano2016">{{cite journal|last1=Zuckerman|first1=Andrea|last2=Romano|first2=Mary|title=Clinical Recommendation: Vulvovaginitis|journal=Journal of Pediatric and AdolescentGynecology|volume=29|issue=6|year=2016|pages=673–679|issn=10833188|doi=10.1016/j.jpag.2016.08.002}}</ref>
*40 to 50% of patients with a prior yeast infection have multiple episodes of yeast infection.<ref name="pmid523355">{{cite journal| author=Hurley R, De Louvois J| title=Candida vaginitis. | journal=Postgrad Med J | year= 1979 | volume= 55 | issue= 647 | pages= 645-7 | pmid=523355 | doi= | pmc=2425644 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=523355  }} </ref>
*Among the adult population 5 to 8% women have more than four episodes of infection.<ref name="pmid9861594">{{cite journal| author=Foxman B, Marsh JV, Gillespie B, Sobel JD| title=Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. | journal=J Womens Health | year= 1998 | volume= 7 | issue= 9 | pages= 1167-74 | pmid=9861594 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9861594  }} </ref>
*In 20% asymptomatic healthy adolescent women, candida species is isolated from the vagina.<ref name="Barousse2004">{{cite journal|last1=Barousse|first1=M M|title=Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents|journal=Sexually Transmitted Infections|volume=80|issue=1|year=2004|pages=48–53|issn=1368-4973|doi=10.1136/sti.2002.003855}}</ref>
 
===Race===
Candida vulvovaginitis is more prevalent among African American women than white American women.<ref name="pmid9861594">{{cite journal| author=Foxman B, Marsh JV, Gillespie B, Sobel JD| title=Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. | journal=J Womens Health | year= 1998 | volume= 7 | issue= 9 | pages= 1167-74 | pmid=9861594 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9861594  }} </ref>
 
==Risk Factors==
The following risk factors have been implicated in predisposing patients to [[Candida]] [[vulvovaginitis]]:
*Previous infection with [[Candida]] [[vulvovaginitis]]<ref name="pmid2305918">{{cite journal |vauthors=Foxman B |title=The epidemiology of vulvovaginal candidiasis: risk factors |journal=Am J Public Health |volume=80 |issue=3 |pages=329–31 |year=1990 |pmid=2305918 |pmc=1404680 |doi= |url=}}</ref>
*Previous infection with ''Neisseria gonorrhea''<ref name="pmid97946644">{{cite journal| author=Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK| title=Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. | journal=Obstet Gynecol | year= 1998 | volume= 92 | issue= 5 | pages= 757-65 | pmid=9794664 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9794664  }}</ref>
*Nulliparity<ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref>
*Luteal phase of the menstrual cycle <ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref>
*Recent [[antibiotic]] use<ref name="pmid12825971">{{cite journal| author=Wilton L, Kollarova M, Heeley E, Shakir S| title=Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. | journal=Drug Saf | year= 2003 | volume= 26 | issue= 8 | pages= 589-97 | pmid=12825971 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12825971  }} </ref>
*[[Pregnancy]]<ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref>
*[[Diabetes Mellitus]]<ref name="pmid11835694">{{cite journal |vauthors=de Leon EM, Jacober SJ, Sobel JD, Foxman B |title=Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes |journal=BMC Infect. Dis. |volume=2 |issue= |pages=1 |year=2002 |pmid=11835694 |pmc=65518 |doi= |url=}}</ref><ref name="pmid12433331">{{cite journal |vauthors=Donders GG |title=Lower Genital Tract Infections in Diabetic Women |journal=Curr Infect Dis Rep |volume=4 |issue=6 |pages=536–539 |year=2002 |pmid=12433331 |doi= |url=}}</ref>
*[[Obesity]]
*[[Immunosuppression]], such as [[HIV]] or [[glucocorticoid]] use<ref name="pmid12636961">{{cite journal |vauthors=Duerr A, Heilig CM, Meikle SF, Cu-Uvin S, Klein RS, Rompalo A, Sobel JD |title=Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity |journal=Obstet Gynecol |volume=101 |issue=3 |pages=548–56 |year=2003 |pmid=12636961 |doi= |url=}}</ref>
*Condom use<ref name="pmid9794664">{{cite journal |vauthors=Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK |title=Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm |journal=Obstet Gynecol |volume=92 |issue=5 |pages=757–65 |year=1998 |pmid=9794664 |doi= |url=}}</ref>
====Risk Factors for Recurrent Candida Vulvovaginitis====
{| class="wikitable"
!Microbial Factors
!Genetic Factors
!Host Behavioural Factors
!Other Risk Factors
|-
|
*Non-albicans Candida species
|
*Lewis blood group non-secretor status
*African American race
*Familial history of recurrent Candida vulvovaginitis
|
*Oral contraceptive
*Sponge/intrauterine device use
*Intercourse frequency/ periodicity<ref name="pmid14709186">{{cite journal| author=Reed BD, Zazove P, Pierson CL, Gorenflo DW, Horrocks J| title=Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. | journal=J Womens Health (Larchmt) | year= 2003 | volume= 12 | issue= 10 | pages= 979-89 | pmid=14709186 | doi=10.1089/154099903322643901 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14709186  }}</ref>
*Orogenital sexual activity
|
*Antibacterial use
*Uncontrolled diabetes
*HIV
*Corticosteroids
*Hormone replacement therapy
|}
<small>Table adopted from Vulvovaginal candidiasis Lancet 2007; 369: 1961–71<ref name="pmid17560449">{{cite journal| author=Sobel JD| title=Vulvovaginal candidosis. | journal=Lancet | year= 2007 | volume= 369 | issue= 9577 | pages= 1961-71 | pmid=17560449 | doi=10.1016/S0140-6736(07)60917-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17560449  }} </ref></small>
 
==Natural History, Complications and Prognosis==
===Natural History===
Candida vulvovaginitis is a common infection of women in reproductive age group. Patients present with vulvar pruritus, dysuria, and vaginal discharge. Half the patients have multiple episodes of the infection and less than 10% have recurrent infection.<ref name="pmid98804752">{{cite journal| author=Fidel PL, Vazquez JA, Sobel JD| title=Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. | journal=Clin Microbiol Rev | year= 1999 | volume= 12 | issue= 1 | pages= 80-96 | pmid=9880475 | doi= | pmc=88907 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9880475  }}</ref>
===Prognosis===
Candida Vulvovaginitis has excellent prognosis with azole therapy. Patients with non Candida albicans infections are prone to have multiple episodes. Treatment with boric acid and oral fluconazole have good prognosis.<ref name="pmid98804753">{{cite journal| author=Fidel PL, Vazquez JA, Sobel JD| title=Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. | journal=Clin Microbiol Rev | year= 1999 | volume= 12 | issue= 1 | pages= 80-96 | pmid=9880475 | doi= | pmc=88907 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9880475  }}</ref>
===Complications===
Candida vulvovaginitis is a self limiting disease with no complications.


==Diagnosis==
==Diagnosis==
Diagnosis of Candida vulvovaginitis requires a correlation of clinical features, microscopic examination, and vaginal culture.
[[Roseola history and symptoms|History and Symptoms]] | [[Roseola physical examination|Physical Examination]] | [[Roseola laboratory findings|Laboratory Findings]] | [[Roseola electrocardiogram|Electrocardiogram]] | [[Roseola chest x ray|Chest X Ray]] | [[Roseola CT|CT]] | [[Roseola MRI|MRI]] | [[Roseola echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Roseola other imaging findings|Other Imaging Findings]] | [[Roseola other diagnostic studies|Other Diagnostic Studies]]
 
===History and Symptoms===
Symptoms of [[vulvovaginitis]] caused by Candida species are indistinguishable and include the following:<ref name="pmid97946642">{{cite journal| author=Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK| title=Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. | journal=Obstet Gynecol | year= 1998 | volume= 92 | issue= 5 | pages= 757-65 | pmid=9794664 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9794664  }}</ref><ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref><ref name="pmid9500475">{{cite journal |vauthors=Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR |title=Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations |journal=Am. J. Obstet. Gynecol. |volume=178 |issue=2 |pages=203–11 |year=1998 |pmid=9500475 |doi= |url=}}</ref>
*Pruritus is the most significant symptom
*Change in the amount and the color of vaginal discharge: It is characterized by a thick, white "cottage cheese-like" vaginal discharge
*Pain on urination ([[dysuria]])
*Pain on sexual intercourse ([[dyspareunia)]]
*[[Vulvovaginal]] soreness
*Symptoms aggravate a week before the menses
 
===Physical Examination===
[[Candida]] [[vulvovaginitis]] requires a careful examination of the external genitalia, the vaginal sidewalls, as well as the cervix. Signs include:<ref name="pmid97946643">{{cite journal| author=Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK| title=Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. | journal=Obstet Gynecol | year= 1998 | volume= 92 | issue= 5 | pages= 757-65 | pmid=9794664 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9794664  }}</ref><ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref>
*Edema and erythema of the vulva and labia
*Fissures and excoriations of the external genitalia
*Thick adherent whitish vaginal discharge
*Cervix is not affected and is normal
 
===Laboratory Findings===
The laboratory findings consistent with the diagnosis of [[Candida]] [[vulvovaginitis]] include:<ref name="pmid16990387">{{cite journal |vauthors=Eckert LO |title=Clinical practice. Acute vulvovaginitis |journal=N. Engl. J. Med. |volume=355 |issue=12 |pages=1244–52 |year=2006 |pmid=16990387 |doi=10.1056/NEJMcp053720 |url=}}</ref><ref name="pmid22519657">{{cite journal |vauthors=Mendling W, Brasch J |title=Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society |journal=Mycoses |volume=55 Suppl 3 |issue= |pages=1–13 |year=2012 |pmid=22519657 |doi=10.1111/j.1439-0507.2012.02185.x |url=}}</ref><ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref>
*[[Vaginal]] pH: In [[Candida]] [[vulvovaginitis]] the [[vaginal]] pH is normal (ranges from 4.0-4.5)
*Wet mount or Saline preparation: It will help in detection of hyphae, clue cells and motile trichomonas differentiating different causes of vaginitis.
*10% Potassium hydroxide preparation: It is more sensitive than wet mount to show budding blastospores or pseudohyphae.
*Culture: Culture for diagnosing [[Candida]] [[vulvovaginitis]] not recommended in patients with positive microscopy. However, it should be done in a symptomatic woman with a negative microscopy and a normal vaginal pH.  Culture using Sabouraud agar, Nickerson’s medium, or Microstix-candida medium identify Candida species with equal sensitivity.
===Approach to patient with Candida Vulvovaginitis===
The following is a algorithm for diagnosis and treatment of vulvovaginal candidiasis :
{{Family tree/start}}
{{Family tree | | | | | | A01 | | | |A01= Symptomatic Vaginitis}}
{{Family tree | | | | | | |!| | | | | }}
{{Family tree | | | | | | |!| | | | | }}
{{Family tree | | | | | | C01 | | | |C01= Abnormal Pelvic Exam}}
{{Family tree | | | | | | |!| | | | | }}
{{Family tree | | | | | | |!| | | | | }}
{{Family tree | | | | | | E01 | | | |E01= Perform Direct microscopy with saline or 10% KOH and estimate pH}}
{{Family tree | | | | | | |!| | | | | }}
{{Family tree | | |,|-|-|-|^|-|-|.|}}
{{Family tree | |F01| | | | |F02| |F01=Direct microscopy negative and pH less than 4.5| F02= Direct microscopy positive}}
{{Family tree | | |!| | | | | | |!| | | | | | }}
{{Family tree | |G01| | | | |G02| | | |G01= Submit culture and consider azole therapy|G02= No culture necessary }}
{{Family tree | | | | | | | | | |!| | | | }}
{{Family tree | | | | | | | |,|-|^|-|-|.| }}
{{Family tree | | | | | | | H01| | |H02|H01= pH<4.5 and no excess WBC's |H02= pH > 4.5 and excess WBC's}}
{{Family tree | | | | | | | |!| | | | |!| }}
{{Family tree | | | | | | |I01| | |I02|I01=Commence Azole therapy|I02= Consider mixed infection}}
{{Family tree/end}}
<small>Algorithm adopted from Vulvovaginal candidiasis Lancet 2007; 369: 1961–71<ref name="pmid17560449">{{cite journal| author=Sobel JD| title=Vulvovaginal candidosis. | journal=Lancet | year= 2007 | volume= 369 | issue= 9577 | pages= 1961-71 | pmid=17560449 | doi=10.1016/S0140-6736(07)60917-9 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17560449  }} </ref></small>


==Treatment==
==Treatment==
===Medical Therapy===
[[Roseola medical therapy|Medical Therapy]] | [[Roseola surgery|Surgery]] | [[Roseola primary prevention|Primary Prevention]] | [[Roseola secondary prevention|Secondary Prevention]] | [[Roseola cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Roseola future or investigational therapies|Future or Investigational Therapies]]
According to, 2016 Update by the Infectious Diseases Society of America medical therapy for Candida vulvovaginitis includes<ref name="PappasKauffman2015">{{cite journal|last1=Pappas|first1=Peter G.|last2=Kauffman|first2=Carol A.|last3=Andes|first3=David R.|last4=Clancy|first4=Cornelius J.|last5=Marr|first5=Kieren A.|last6=Ostrosky-Zeichner|first6=Luis|last7=Reboli|first7=Annette C.|last8=Schuster|first8=Mindy G.|last9=Vazquez|first9=Jose A.|last10=Walsh|first10=Thomas J.|last11=Zaoutis|first11=Theoklis E.|last12=Sobel|first12=Jack D.|title=Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America|journal=Clinical Infectious Diseases|year=2015|pages=civ933|issn=1058-4838|doi=10.1093/cid/civ933}}</ref>:
*Uncomplicated candida Vulvovaginits:
**1st line :Any topical antifungal agents can be used and all of them have equal efficacy
**Alternative : Single 150mg dose of oral fluconazole is recommended.
*Severe acute Candida vulvovaginitis:
**1st line: Oral fluconazole 150mg, given every 72 hours for a total of 2 or 3doses
*Candida glabrata: When unresponsive to oral azoles
**1st line: Topical intravaginal boric acid administered in a gelatin capsule, 600mg daily for 14days
**2nd line: Nystatin intravaginal suppositories, 100,000 units daily for 14days
**3rd line: Topical 17% flucytosine cream alone or in combination with amphotericin B cream daily for 14days
*Recurring vulvovaginal candidiasis:
**1st line: 10 to 14days of induction therapy with a topical agent or oral fluconazole, followed by fluconazole, 150mg weekly for 6months
====Candida Vulvovaginitis in HIV positive women====
*Treatment of symptomatic Candida vulvovaginitis and the recurrence in HIV-positive women is similar to that of HIV-negative individuals.
 
===Surgical Therapy===
There are no surgical options for Candida vulvovaginitis.
 
==Prevention==
===Primary Prevention===
*There are no primary preventive measures for candidal infection.
===Secondary Prevention===
*Prophylactic maintainence of fluconazole is helpful in patients with idiopathic recurrent candida vulvovaginitis and in secondary recurrent vulvovaginitis associated with lichen sclerosus or topical estrogen application.ref name="pmid17560449">{{cite journal |vauthors=Sobel JD |title=Vulvovaginal candidosis |journal=Lancet |volume=369 |issue=9577 |pages=1961–71 |year=2007 |pmid=17560449 |doi=10.1016/S0140-6736(07)60917-9 |url=}}</ref>


==References==
==Case Studies==
{{Reflist|2}}
[[Roseola case study one|Case #1]]

Latest revision as of 19:04, 22 May 2017


Roseola Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Roseola from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sandbox: Reddy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox: Reddy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox: Reddy

CDC on Sandbox: Reddy

Sandbox: Reddy in the news

Blogs on Sandbox: Reddy

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Sandbox: Reddy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]


Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Any Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:_Reddy&oldid=1312758"